BR0014062A - Formulações para uso parenteral de fosfato de estramustina e sulfoalquileter ciclodextrinas - Google Patents

Formulações para uso parenteral de fosfato de estramustina e sulfoalquileter ciclodextrinas

Info

Publication number
BR0014062A
BR0014062A BR0014062-7A BR0014062A BR0014062A BR 0014062 A BR0014062 A BR 0014062A BR 0014062 A BR0014062 A BR 0014062A BR 0014062 A BR0014062 A BR 0014062A
Authority
BR
Brazil
Prior art keywords
formulations
estramustine phosphate
parenteral use
formulation
phosphate
Prior art date
Application number
BR0014062-7A
Other languages
English (en)
Inventor
Lorena Muggetti
Paolo Colombo
Alessandro Martini
Giovanni Buzzi
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of BR0014062A publication Critical patent/BR0014062A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"FORMULAçõES PARA USO PARENTERAL DE FOSFATO DE ESTRAMUSTINA E SULFOALQUILETER CICLODEXTRINAS". Uma formulação farmacêutica caracterizada por compreender um carreador ou diluente aceitável parenteralmente, fosfato de estramustina e uma sulfoalquileter ciclodextrina. A formulação pode ser administrada de acordo com um regime de quimioterapia combinada em associação com um ou mais agentes quimioterapêuticos. A formulação também possibilita a administração de fosfato de estramustina sem efeitos colaterais no local da injeção.
BR0014062-7A 1999-09-16 2000-08-03 Formulações para uso parenteral de fosfato de estramustina e sulfoalquileter ciclodextrinas BR0014062A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921958.6A GB9921958D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
PCT/EP2000/007680 WO2001019339A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins

Publications (1)

Publication Number Publication Date
BR0014062A true BR0014062A (pt) 2002-12-31

Family

ID=10861068

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0014062-7A BR0014062A (pt) 1999-09-16 2000-08-03 Formulações para uso parenteral de fosfato de estramustina e sulfoalquileter ciclodextrinas

Country Status (19)

Country Link
US (1) US6730664B1 (pt)
EP (1) EP1212041A1 (pt)
JP (1) JP2003509356A (pt)
KR (1) KR20020059401A (pt)
CN (1) CN1374857A (pt)
AU (1) AU777684B2 (pt)
BR (1) BR0014062A (pt)
CA (1) CA2385065A1 (pt)
CZ (1) CZ2002944A3 (pt)
EA (1) EA003936B1 (pt)
GB (1) GB9921958D0 (pt)
HU (1) HUP0300185A3 (pt)
IL (1) IL148408A0 (pt)
MX (1) MXPA02002855A (pt)
NO (1) NO20021270L (pt)
PL (1) PL356026A1 (pt)
SK (1) SK3462002A3 (pt)
WO (1) WO2001019339A1 (pt)
ZA (1) ZA200201744B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869939B2 (en) * 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
EP1954292B1 (en) * 2005-11-28 2014-05-07 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
US7658913B2 (en) * 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
US20110207764A1 (en) * 2010-02-23 2011-08-25 Valery Alakhov Cyclopolysaccharide compositions
US8383663B2 (en) 2010-07-19 2013-02-26 Supratek Pharma Inc. Bendamustine anionic-catioinic cyclopolysaccharide compositions
WO2024074600A1 (en) * 2022-10-05 2024-04-11 Institut Gustave Roussy An oral liquid composition of vinorelbine

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523035A (en) * 1976-03-10 1978-08-31 Leo Ab Derivatives of estradiol - 17 - dihydrogen phosphates
JPS59108800A (ja) 1982-12-13 1984-06-23 Japan Atom Energy Res Inst 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子
CA1260393A (en) * 1984-10-16 1989-09-26 Lajos Tarcsay Liposomes of synthetic lipids
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
GB9419153D0 (en) 1994-09-22 1994-11-09 Erba Carlo Spa Estramustine formulations with improved pharmaceutical properties
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US20020039594A1 (en) 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
WO2001019339A1 (en) 2001-03-22
MXPA02002855A (es) 2003-07-21
AU777684B2 (en) 2004-10-28
EA003936B1 (ru) 2003-10-30
JP2003509356A (ja) 2003-03-11
NO20021270D0 (no) 2002-03-14
NO20021270L (no) 2002-03-14
EA200200370A1 (ru) 2002-10-31
CZ2002944A3 (cs) 2002-08-14
KR20020059401A (ko) 2002-07-12
CA2385065A1 (en) 2001-03-22
SK3462002A3 (en) 2002-08-06
EP1212041A1 (en) 2002-06-12
HUP0300185A2 (en) 2003-05-28
CN1374857A (zh) 2002-10-16
GB9921958D0 (en) 1999-11-17
ZA200201744B (en) 2004-01-28
US6730664B1 (en) 2004-05-04
PL356026A1 (en) 2004-05-31
HUP0300185A3 (en) 2007-02-28
IL148408A0 (en) 2002-09-12
AU6993900A (en) 2001-04-17

Similar Documents

Publication Publication Date Title
TR200002299T2 (tr) Epotilon kompozisyonları.
BR0109931A (pt) Composições farmacêuticas
BR0014071A (pt) Formulações para uso parenteral de fosfato de estramustina e aminoácidos
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
BR9911046A (pt) Uso de antidepressivos tricìclicos para analgesia local
AU2274201A (en) Compounds and compositions for delivering active agents
PL347671A1 (en) Compounds and compositions for delivering active agents
EP0993831A3 (en) Compounds and compositions for delivering active agents
ES2116292T3 (es) Aminoesteroides para uso oftalmico.
ZA200106499B (en) Methods for treating ovarian cancer, poly(phosphoester) compositions, and biodegradable articles for same.
TR200003108T2 (tr) İlaç kompozisyonları
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
NZ501235A (en) Topical compositions containing emulsion of a discontinuous phase which is an eutectic mixture of two pharmaceutical agents and a continuous phase
DE60137960D1 (de) Pharmazeutische zusammensetzungen mit corticosteroiden und antiinfektiva
PL359624A1 (en) Clear aqueous anaesthetic composition
SV2002000137A (es) Productos farmaceuticos beta-carbolina ref n. 29342/36539 el
BR0014062A (pt) Formulações para uso parenteral de fosfato de estramustina e sulfoalquileter ciclodextrinas
DE60223542D1 (de) Zusammensetzung mit fulvestrant
ATE311904T1 (de) Halbfester verabreichungsträger und arzneimittel
BR0014063A (pt) Formulações papa uso parenteral de fosfato de estramustina com propriedades farmacológicas melhoradas
BR0013276A (pt) Formulação farmacêutica para uso parenteral que compreende fosfato de estramustina, como ingrediente ativo
ES2191241T3 (es) Preparaciones farmaceuticas por via oral que comprenden s-(3-hidroxipropil)-l-cisteina.
NZ501987A (en) Single, high dosage intravenous administration of estramustine phosphate
MX2023013033A (es) Formulaciones farmaceuticas.
MXPA01003340A (es) Composiciones farmaceuticas en base a alfa-ciclodextrina para la administracion por via oral de analogos de lh-rh.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A, 8A E 9A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009.